CD7 CAR-T therapy

CD7 CAR-T therapy is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD7 antigen, a 40-kDa transmembrane glycoprotein highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Because CD7 is also expressed on normal T cells and natural killer (NK) cells, the development of these therapies often requires specialized engineering to prevent fratricide (self-killing of the CAR-T cells), such as the genomic deletion of the CD7 gene using CRISPR/Cas9 or the use of protein expression blockers. Clinical research, including studies from institutions like Hebei Yanda Lu Daopei Hospital, has demonstrated that CD7 CAR-T therapy can achieve high complete remission rates and serve as an effective bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed or refractory disease. Monitoring of post-transplant CAR-T cell persistence and cytokine levels (e.g., IL-6, IL-10) is used to predict outcomes and complications like graft-versus-host disease (GVHD).

Other names

CD7-targeted CAR-TCD-7-targeted CAR-TCD 7-targeted CAR-Tanti-CD7 CAR-Tanti-CD-7 CAR-Tanti-CD 7 CAR-TCD7 CAR-TCD-7 CAR-TCD 7 CAR-T